Fortress Biotech Inc - ESG Rating & Company Profile powered by AI
The ESG score covers seventeen UN SDGs including: 'Good Health & Wellbeing', 'Reduced Inequalities' and 'Partnerships for the Goals'. This assessment of Fortress Biotech Inc is prepared by All Street Sevva using cutting edge NLP. The Sustainability score for Fortress Biotech Inc represents the company's reporting of the United Nations SDGs.
Fortress Biotech Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 4.1; made up of an environmental score of 6.0, social score of 3.2 and governance score of 3.2.
4.1
Medium ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
969 | Vertex Pharmaceuticals Inc | 4.2 | High |
969 | Zentalis Pharmaceuticals Inc | 4.2 | High |
989 | Fortress Biotech Inc | 4.1 | High |
989 | Advanz Pharma Corp Ltd | 4.1 | High |
989 | Abeona Therapeutics Inc | 4.1 | High |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Fortress Biotech Inc have an accelerator or VC vehicle to help deliver innovation?
Does Fortress Biotech Inc disclose current and historical energy intensity?
Does Fortress Biotech Inc report the average age of the workforce?
Does Fortress Biotech Inc reference operational or capital allocation in relation to climate change?
Does Fortress Biotech Inc disclose its ethnicity pay gap?
Does Fortress Biotech Inc disclose cybersecurity risks?
Does Fortress Biotech Inc offer flexible work?
Does Fortress Biotech Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Fortress Biotech Inc disclose the number of employees in R&D functions?
Does Fortress Biotech Inc conduct supply chain audits?
Does Fortress Biotech Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Fortress Biotech Inc conduct 360 degree staff reviews?
Does Fortress Biotech Inc disclose the individual responsible for D&I?
Does Fortress Biotech Inc disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Fortress Biotech Inc disclose current and / or historical scope 2 emissions?
Does Fortress Biotech Inc disclose water use targets?
Does Fortress Biotech Inc have careers partnerships with academic institutions?
Did Fortress Biotech Inc have a product recall in the last two years?
Does Fortress Biotech Inc disclose incidents of discrimination?
Does Fortress Biotech Inc allow for Work Councils/Collective Agreements to be formed?
Has Fortress Biotech Inc issued a profit warning in the past 24 months?
Does Fortress Biotech Inc disclose parental leave metrics?
Does Fortress Biotech Inc disclose climate scenario or pathway analysis?
Does Fortress Biotech Inc disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Fortress Biotech Inc disclose the pay ratio of women to men?
Does Fortress Biotech Inc support suppliers with sustainability related research and development?
Does Fortress Biotech Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Fortress Biotech Inc reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Fortress Biotech Inc involved in embryonic stem cell research?
Does Fortress Biotech Inc disclose GHG and Air Emissions intensity?
Does Fortress Biotech Inc disclose its waste policy?
Does Fortress Biotech Inc report according to TCFD requirements?
Does Fortress Biotech Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Fortress Biotech Inc disclose energy use targets?
Does Fortress Biotech Inc disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Fortress Biotech Inc have a policy relating to cyber security?
Have a different question?
Potential Risks for Fortress Biotech Inc
These potential risks are based on the size, segment and geographies of the company.
Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; ConVax; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Island, New York.